|View printer-friendly version|
|BACE Inhibitor BI 1181181 Voluntarily Put on Temporary Clinical Hold for Safety Evaluation|
"Our partner is working diligently to evaluate and understand this observation," said Dr.
About Alzheimer's Disease
Alzheimer's disease is the most common type of dementia and is increasing in prevalence as the population ages. According to the
About BI 1181181
BI 1181181 is
For additional information, please visit the company's website at www.vitaepharma.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the clinical development of BI 1181181 and any back up compounds. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties and may turn out to be wrong. For example, our statements about the future advancement of BI 1181181 or its structurally distinct, Phase 1-ready back up could be affected by the results of Boehringer Ingelheim's evaluations of the studies to date, the future identification of additional side effects or other safety issues, the fact that we are developing BI 1181181 as part of a collaboration and relying on a third party to conduct the trials and the other inherent risks of clinical development. Furthermore, the results of preclinical and clinical trials conducted to date may not be predictive of future results. Vitae's product candidates are at an early stage of development and contain a high level of development risk. All of our forward-looking statements are subject to risks detailed in our filings with the U.S. Securities and Exchange Commission, including the Company's Registration Statement on Form S-1, as amended (Form S-1), and the prospectus filed in connection with the Form S-1. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vitae undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.